CA-FORESCOUT-TECH
6.6.2022 15:02:12 CEST | Business Wire | Press release
Forescout Technologies, Inc. , the global leader in automated cybersecurity, today announced that it has signed a definitive agreement to acquire Cysiv , a cybersecurity innovator that uses its cloud platform to improve detection and response of true threats. With this acquisition, Forescout will leverage Cysiv’s threat detection engine to analyze a wealth of asset and network communications data automatically collected by Forescout’s platform. This comprehensive data across IT, IoT, OT and IoMT devices, as well as other essential data sources, enables better true threat detection and response so customers can operate more securely and efficiently. Upon the close of the acquisition, Cysiv will join Forescout.
“Organizations need to be able to reduce the billions of data points on their networks to a handful of actionable true threats – automatically. Together with Cysiv, Forescout will provide customers with the most powerful platform for automated cybersecurity across their digital terrains,” said Wael Mohamed, CEO of Forescout. “Upon close, the acquisition will help our customers leverage actionable threat intelligence from comprehensive data collected by Forescout and analyzed by Cysiv. We will receive far more than just great technology in this acquisition. The Cysiv team is exceptional, and our two organizations are highly complementary.”
Today, organizations are faced with the immense pressure to secure their networks. CIOs and CISOs have experienced rapid growth in the volume and diversity of managed and unmanaged devices, including IoT devices, that has given rise to increased risks and cybersecurity threats, coinciding with a drop in available cybersecurity resources. With the rapid adoption of cloud, and a cloud-first mindset that’s been accelerated by the work-from-anywhere shift of the past two years, enterprises are particularly concerned with managing threats to these fluid threat environments. This has resulted in organizations not being able to effectively manage the detection, investigation, escalation and response of true threats, particularly as the threat landscape and unmanaged device landscape have become more complex.
Existing solutions for threat detection and response, such as EDR, require the use of agents on managed devices. This means that organizations dependent on an agent-based approach for threat detection and response are not able to look for threats coming from the majority of their connected devices, particularly critical assets like IoT, IoMT and OT.
For over a decade, Forescout’s ability to deeply integrate into the fabric of customers’ networks has enabled it to collect real-time data for all connected assets and users, together with the communications among those assets and users. Customers have been asking Forescout to leverage this comprehensive data to provide greater insight into threats for all types of assets and to enable faster, more automated response and remediation.
“We have always been on a mission to provide better threat detection and faster response,” said Partha Panda, CEO and co-founder of Cysiv. “After successfully partnering together for the last year, we are thrilled to join Forescout as we continue on the next stage of our journey. The combination of Forescout and Cysiv will provide organizations with best-in-class threat detection together with automated incident prioritization and automated response.”
The acquisition is expected to close in July, 2022, subject to the satisfaction of closing conditions and receipt of applicable regulatory approvals and comes on the heels of its acquisition of CyberMDX which further strengthens Forescout’s industry-leading IT, IoT and OT device coverage with IoMT expertise.
About Forescout
Forescout Technologies, Inc. delivers cybersecurity automation across the digital terrain, maintaining continuous alignment of customers’ security frameworks with their digital realities, including all asset types. The Forescout Continuum Platform provides complete asset visibility, continuous compliance, network segmentation and a strong foundation for Zero Trust. For more than 20 years, Fortune 100 organizations and government agencies have trusted Forescout to provide automated cybersecurity at scale. Forescout arms customers with data-powered intelligence to accurately detect risks and quickly remediate cyberthreats without disruption of critical business assets. www.forescout.com
Managing cyber risk, together.
© 2022 Forescout Technologies, Inc. All rights reserved. Forescout Technologies, Inc. is a Delaware corporation. A list of our trademarks and patents can be found at https://www.forescout.com/company/legal/intellectual-property-patents-trademarks . Other brands, products, or service names may be trademarks or service marks of their respective owners.
About Cysiv
Cysiv security operations center (SOC)-as-a-service provides enterprises with better detection and faster response of true threats. We do this by uniquely combining our cloud-native next generation SIEM, with a data-centric approach and a team of experts that operate as a seamless extension of your SOC. All of this is delivered as a subscription-based service, with predictable and flexible pricing, that can be operational in weeks. Cysiv’s modern approach to threat detection and response helps reduce risk, ensure compliance, and improve the efficiency, effectiveness and maturity of your security operations. To learn more, visit www.cysiv.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220606005321/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 15:29:00 CET | Press release
Pending the European Commission decision, Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) will be the first PD-1 immunotherapy treatment for patients with advanced squamous cell carcinoma of the anal canal (SCAC) in EuropeGlobally, the prevalence of SCAC is estimated at around 1 or 2 cases per 100,000 people, with a higher incidence in women than in men1,2,3The Committee for Medicinal Products for Human Use (CHMP) positive opinion is based on data from the Phase 3 POD1UM-303/InterAACT2 trial which showed patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment4 Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (
Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 13:32:00 CET | Press release
Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,
BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 09:00:00 CET | Press release
The Latest Players and AI Capabilities Drive Captivating, Personalized, and Interactive Signage With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerfu
Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 08:30:00 CET | Press release
Iconic Vbeam® Pro and Matrix™ Systems showcased ahead of broader commercial availability Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, suppo
Merz Therapeutics Appoints Dan Staner as President, Region Europe30.1.2026 08:00:00 CET | Press release
Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerating its growth strategy across key European markets. “Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe,” said Stefan König, CEO of Merz Therapeutics. “His deep commercial, strategic, and regional leadership experience will be instrumental in advancing our growth ambitions, expanding patient access to our therapies, and further strengthening our presence in Europe. We are very pleased to welcome Dan to Merz Therapeutics.” Throughout his career, Dan has held senior leadership roles i
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
